Evidence map›Paper›PMID 27502395›Full record

ArticleOral and maxillofacial surgery2016

Correlation between invasion mode and the histologic risk assessment model in oral squamous cell carcinoma.

Mojgan Alaeddini, Shahroo Etemad-Moghadam

Abstract read
PubMed Publisher
In one paragraph

Article in Oral and maxillofacial surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mojgan AlaeddiniDental Research Center, Dentistry Research Institute, Tehran University of Medical Sciences, Ghods St, Enghelab Ave, P.O. Box: 14155-5583, 14174, Tehran, Iran.
Shahroo Etemad-MoghadamDental Research Center, Dentistry Research Institute, Tehran University of Medical Sciences, Ghods St, Enghelab Ave, P.O. Box: 14155-5583, 14174, Tehran, Iran. shahrooetemad@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe histologic risk assessment (HRA) model was proposed to assess clinical outcome of oral squamous cell carcinomas (SCCs), and its prognostic value has been confirmed in several studies, but its underlying molecular mechanisms has not been fully investigated. The objective of this study was to evaluate the association between immunohistochemical invasion mode of head and neck SCC and the HRA grading system.

methodsThe HRA model consisting of risk scores (RSs), based on perineural invasion (PI), lymphocytic infiltration (LI), and worst pattern of invasion (WPOI), was used for grading 80 samples of head and neck SCC, followed by immunohistochemical staining with antibodies against E-cadherin, N-cadherin, and podoplanin. The two major invasion modes were considered as epithelial-mesenchymal-transition (EMT) and collective cell invasion (CCI) with profiles of E-cadherin

resultsInvasion pattern was significantly different among the three RSs (P = 0.01) and across the different scores of LI (P = 0.03) but not perineural invasion (PNI) (P = 0.07) and WPOI (P = 0.70).

conclusionsBased on our results, it seems that there is a difference in EMT, CCI, and partial/incomplete EMT among the variables of the HRA model which might help clarify its functioning system.

Indexed as

CadherinsCarcinoma, Squamous CellHumansLymphatic MetastasisMembrane GlycoproteinsMouth NeoplasmsNeoplasm GradingNeoplasm InvasivenessPodoplaninPrognosisRisk AssessmentCadherinsMembrane GlycoproteinsPDPN protein, humanPodoplaninCarcinomaEpithelial-mesenchymal-transitionMouthSquamous cell

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.